Abstract:The heterogeneity of Hepatocellular Carcinoma (HCC) poses a barrier to effective treatment. Stratifying highly heterogeneous HCC into molecular subtypes with similar features is crucial for personalized anti-tumor therapies. Although driver genes play pivotal roles in cancer progression, their potential in HCC subtyping has been largely overlooked. This study aims to utilize driver genes to construct HCC subtype models and unravel their molecular mechanisms. Utilizing a novel computational framework, we expanded the initially identified 96 driver genes to 1192 based on mutational aspects and an additional 233 considering driver dysregulation. These genes were subsequently employed as stratification markers for further analyses. A novel multi-omics subtype classification algorithm was developed, leveraging mutation and expression data of the identified stratification genes. This algorithm successfully categorized HCC into two distinct subtypes, CLASS A and CLASS B, demonstrating significant differences in survival outcomes. Integrating multi-omics and single-cell data unveiled substantial distinctions between these subtypes regarding transcriptomics, mutations, copy number variations, and epigenomics. Moreover, our prognostic model exhibited excellent predictive performance in training and external validation cohorts. Finally, a 10-gene classification model for these subtypes identified TTK as a promising therapeutic target with robust classification capabilities. This comprehensive study provides a novel perspective on HCC stratification, offering crucial insights for a deeper understanding of its pathogenesis and the development of promising treatment strategies. Dividing highly heterogeneous HCC into molecular subtypes with similar characteristics is crucial for personalized anti-tumor therapies. Although driver genes play pivotal roles in cancer progression, their potential in HCC subtyping has been largely overlooked. In this work, we developed a multi-omics network-based stratification algorithm that utilizes patient mutation data and requires smaller computational resources for subtype assignment. Through this algorithm, we categorized HCC into two subtypes, CLASS A and CLASS B. Using multi-omics and single-cell data, we identified differences between these subtypes in gene expression, methylation, immune infiltration, and other aspects. Beyond subtype characterization, our study established a robust clinical prediction model (https://mike-wang-bjut.shinyapps.io/DynNomapp_HCC_Sutypes/) incorporating subtype information and typical clinical features, enabling precise survival predictions. Finally, we developed a high-performing machine learning classifier for our subtype. Analyzing this classification model and reviewing previous experimental papers, we identified TTK as a potential diagnostic marker and therapeutic target specific to our subtypes. In conclusion, our research offers a novel perspective on HCC stratification, which is crucial for a deeper understanding of its pathogenesis and developing promising treatment strategies.

Cell-type specific subtyping of epigenomes improves prognostic stratification of cancer

Identification of Molecular Subtypes for Integrated Multi-Omics Analysis for Use in Guiding Precision Medicine in Hepatocellular Carcinoma.

Genome-Wide DNA Methylation and Gene Expression Profiling Characterizes Molecular Subtypes of Esophagus Squamous Cell Carcinoma for Predicting Patient Survival and Immunotherapy Efficacy

DNA methylation-based classification and identification of renal cell carcinoma prognosis-subgroups

Discovery and Construction of Prognostic Model for Clear Cell Renal Cell Carcinoma Based on Single-Cell and Bulk Transcriptome Analysis

DNA methylation profiling deciphers three EMT subtypes with distinct prognoses and therapeutic vulnerabilities in breast cancer

Integrative Multiomics Analyses Identify Molecular Subtypes of Head and Neck Squamous Cell Carcinoma with Distinct Therapeutic Vulnerabilities

Integrative analysis of single-cell and bulk multi-omics data to reveal subtype-specific characteristics and therapeutic strategies in clear cell renal cell carcinoma patients

Predictors of breast cancer cell types and their prognostic power in breast cancer patients

Multi-omics clustering analysis carries out the molecular specific subtypes of thyroid carcinoma: implicating for the precise treatment strategies

Integrative Multi-Omics Analyses Identify Molecular Subtypes of Head and Neck Squamous Cell Carcinoma with Distinct Therapeutic Vulnerabilities

Decoding Liver Cancer Prognosis: From Multi-omics Subtypes, Prognostic Models to Single Cell Validation

Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities

Molecular subtypes based on DNA methylation predict prognosis in colon adenocarcinoma patients

Immune depletion of the methylated phenotype of colon cancer is closely related to resistance to immune checkpoint inhibitors

Multi-omics comprehensive analysis of renal clear cell carcinoma to distinguish subtypes with different molecular characterizations and therapeutic strategies

Subtype-based Analysis of Cell-in-cell Structures in Non-Small Cell Lung Cancer.

Machine learning and multi-omics data reveal driver gene-based molecular subtypes in hepatocellular carcinoma for precision treatment

Multi-omics characterization and machine learning of lung adenocarcinoma molecular subtypes to guide precise chemotherapy and immunotherapy

Epithelial–Mesenchymal Transition-Based Gene Signature and Distinct Molecular Subtypes for Predicting Clinical Outcomes in Breast Cancer

Molecular subtypes based on DNA promoter methylation predict prognosis in lung adenocarcinoma patients